Inimmune

09/22/2026

09/15/2026

Building on the recent DCVMN webinar, “Innovative Adjuvants for Advancing Global Health,” which aired on September 9 and is now available online, Dr. Juhienah Khalaf (Director of Adjuvant Portfolio at Inimmune) and Ariana Meirelles (Global Marketing Manager, Vaccine Adjuvants at SPI) are heading to the DCVMN Annual General Meeting!
Watch the webinar: https://dcvmn.org/webinar/innovative-adjuvants-for-advancing-global-health/
Join us at Booth B1 in Beijing to explore Inimmune and SPI’s innovative adjuvant portfolios—and discover how we’re helping shape the future of global health. 💉🔬

Adjuvants have transformed vaccine development, but many leading systems remain unavailable for licensing. In this webinar, SPI Pharma and Inimmune will present globally licensable, scalable adjuvant platforms, including T4Q, T4QGH, T4SE, and T4AH, powered by affordable and stable MPL analogue, INI-...

08/24/2026

Inimmune is teaming up with SPI Pharma for a webinar spotlighting globally licenseable and scalable adjuvant technologies for next-generantion vaccine development.

Dr. Juhienah Khalaf (Inimmune) and Peter Tygesen (SPI Pharma) will explore proven adjuvant platforms including QS-21, TLR4 agonist-based liposomal systems and squalene- and alum- based technologies formulated with a synthetic MPL analogue. The conversation will also cover INI-2002 an affordable and stable TLR4 agonist supporting the development of next-generation adjuvant systems and how these platforms can deliver strong immunogenicity and favorable safety profiles at a cost effective price point.

This session is built for anyone working in vaccine R&D, adjuvant research, preclinical and translational development, business development and licensing, or global health accessibility initiatives.

06/29/2026

For millions of people living with allergies, everyday moments, from meals to time outdoors, require constant vigilance.

Innovation in allergy treatment isn’t just about science. It’s about reducing that burden and improving quality of life.

That’s what drives our work at Inimmune.

hashtag hashtag hashtag

06/09/2026

Innovation is driven by people.

At Inimmune, our team brings together deep expertise in immunology, clinical development, and translational science – all focused on advancing new solutions for patients.

Learn more about us: https://inimmune.com/

06/05/2026

Inimmune is proud that our very own scientists have been published again.

Mizuno et al. describe the synthesis of a human-selective STING agonist, INI3069, that activates conventional TBK1-mediated cellular processes such as IRF3 phosphorylation and ISG expression while blocking TBK1-independent phenotypes including TFEB activation, autophagy, and Golgi trafficking. Using...

06/02/2026

is around the corner!

Inimmune will be participating in this year’s meeting, where our CEO, David Burkhart, Ph.D., is scheduled to present on our approach to advancing disease-modifying and progress from our INI-2004 program.

📍 June 24, 4:15-4:30 p.m. PT

Learn more: https://convention.bio.org/speakers/david-burkhart

Innovation Organization

05/04/2026

May is , a month dedicated to helping patients and families educate their communities and advocate for safety.

Food allergies may be unseen, but they should never be unnoticed. At Inimmune, we’re advancing our allergy program with the needs of millions of people worldwide living with in mind.

04/22/2026

Our CEO, David Burkhart, Ph.D., will present at the Food Allergy Fund Summit taking place April 29, 2026, in NYC.

Dr. Burkhart will join leaders advancing new approaches to treatment and prevention to discuss translating science into solutions for patients with food allergies.

We look forward to joining these critical conversations shaping the future of research and innovation.

Check out the agenda here: https://foodallergyfund.org/summit2026

04/08/2026

What does it take to develop a disease-modifying therapy for allergic rhinitis?

In a recent interview with Leader’s Proch, our CEO Burkhart shares how Inimmune is advancing INI-2004, a novel intranasal designed to reprogram the immune system and deliver durable responses for patients.

The discussion also explores the nuances of clinical trials, from seasonal timing to the role of controlled chamber studies in improving signal detection.

Read more: https://www.clinicalleader.com/doc/considerations-for-allergic-rhinitis-trials-are-nothing-to-sneeze-at-0001

Inimmune CEO David Burkhart explains how a GSK layoff led to the formation of a new company focused on treating allergic rhinitis. Here, he shares success from the companys approach to site selection, trial design, and timing.